Bio-Path Holdings Reports Full Year 2020 Financial Results
March 10, 2021 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, March 10, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Bio-Path Holdings to Announce Full Year 2020 Financial Results on March 10, 2021
March 03, 2021 16:01 ET
|
Bio-Path Holdings, Inc.
HOUSTON, March 03, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings, Inc. Announces Closing of $13.0 Million Public Offering of Common Stock
February 18, 2021 16:01 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Bio-Path Holdings, Inc. Announces Pricing of $13.0 Million Public Offering of Common Stock
February 16, 2021 07:15 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock
February 13, 2021 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Feb. 13, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Bio-Path Receives Third U.S. Patent Grant Related to Manufacture of Platform Technology
February 10, 2021 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002
November 19, 2020 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to...
Bio-Path Holdings Reports Third Quarter 2020 Financial Results
November 13, 2020 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to...
Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020
November 06, 2020 08:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of Cancers
October 22, 2020 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...